Literature DB >> 14696748

Kinetics of hepatitis C virus load during hemodialysis: novel perspectives.

Fabrizio Fabrizi1, Suphamai Bunnapradist, Giovanna Lunghi, Paul Martin.   

Abstract

Hepatitis C virus (HCV) infection remains frequent among dialysis patients. The relationship between viral load and liver disease progression is currently a matter of debate; however, low HCV viral load (HCV RNA) is a well established predictor of successful antiviral treatment. Dialysis patients have immune compromise due to uremia; in spite of this, HCV viral load is not high and does not increase over time. A number of studies support the notion that this dynamics of HCV viral load may be related to lowering of HCV RNA titers during the HD procedure. It has been suggested that the intradialytic reduction of HCV is membrane-dependent; polysulphone (PS) and hemophan membranes appear more effective. Various mechanisms have been mentioned to explain the reduction of HCV RNA during hemodialysis (HD): adsorption of HCV onto dialysis membrane, HCV escape into spent dialysate, destruction of HCV particles or increased interferon (IFN) activity. Several investigators have noted that, at the end of the HD procedure, a virological rebound of HCV viremia occurs. Some suggestions have been made to minimize the risk for HCV escape into spent dialysate. However, controversial evidence on these issues exists: the HCV RNA reduction during HD procedures has not been seen in some studies and the relationship between the intra-dialytic reduction of HCV RNA titers and dialysis membrane is not completely understood. It is evident that additional long-term longitudinal studies by serial viral load estimations are needed to better define the dynamics of HCV viral load in the dialysis population.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14696748

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  10 in total

Review 1.  Management of hepatitis C in patients with chronic kidney disease.

Authors:  Roberto J Carvalho-Filho; Ana Cristina C A Feldner; Antonio Eduardo B Silva; Maria Lucia G Ferraz
Journal:  World J Gastroenterol       Date:  2015-01-14       Impact factor: 5.742

2.  Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection.

Authors:  Jan Sperl; Sona Frankova; Renata Senkerikova; Magdalena Neroldova; Vaclav Hejda; Miroslava Volfova; Dusan Merta; Ondrej Viklicky; Julius Spicak; Milan Jirsa
Journal:  World J Gastroenterol       Date:  2015-05-14       Impact factor: 5.742

3.  Hepatitis C is less aggressive in hemodialysis patients than in nonuremic patients.

Authors:  Jose Eduardo Trevizoli; Raissa de Paula Menezes; Lara Franciele Ribeiro Velasco; Regina Amorim; Mauro Birche de Carvalho; Liliana Sampaio Mendes; Columbano Junqueira Neto; José Roberto de Deus Macedo; Francisco de Assis; Rocha Neves
Journal:  Clin J Am Soc Nephrol       Date:  2008-07-23       Impact factor: 8.237

Review 4.  Hepatocyte growth factor (HGF) and hemodialysis: physiopathology and clinical implications.

Authors:  Carmelo Libetta; Pasquale Esposito; Claudia Martinelli; Fabrizio Grosjean; Marilena Gregorini; Teresa Rampino; Antonio Dal Canton
Journal:  Clin Exp Nephrol       Date:  2015-12-16       Impact factor: 2.801

5.  Acute hepatitis C virus infection assessment among chronic hemodialysis patients in the Southwest Parana State, Brazil.

Authors:  Maricea Engel; Fernanda M Malta; Michele M S Gomes; Isabel M V G C Mello; João R R Pinho; Suzane K Ono-Nita; Flair J Carrilho
Journal:  BMC Public Health       Date:  2007-04-04       Impact factor: 3.295

6.  Detection of hepatitis C virus in patients with terminal renal disease undergoing dialysis in southern Brazil: prevalence, risk factors, genotypes, and viral load dynamics in hemodialysis patients.

Authors:  Beatris Maria Vidales-Braz; Naylê Maria Oliveira da Silva; Rubens Lobato; Fabiana Nunes Germano; Luiza Dias da Mota; Elvino J G Barros; Ana Maria Barral de Martinez
Journal:  Virol J       Date:  2015-02-03       Impact factor: 4.099

7.  Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease.

Authors:  Eric Lawitz; Edward Gane; Eric Cohen; John Vierling; Kosh Agarwal; Tarek Hassanein; Parvez S Mantry; Paul J Pockros; Michael Bennett; Nyingi Kemmer; Giuseppe Morelli; Jiuhong Zha; Deli Wang; Nancy S Shulman; Daniel E Cohen; K Rajender Reddy
Journal:  Kidney Int Rep       Date:  2018-10-09

8.  Hepatitis C Genotype Prevalence in Monastir Region, Tunisia: Correlation between 5' Untranslated Region (5'UTR), Non-structural 5B (NS5B), and Core Sequences in HCV Subtyping.

Authors:  Amira Souii; Aida Elargoubi; Catherine Fallecker; Maha Mastouri; Emmanuel Drouet
Journal:  Curr Microbiol       Date:  2016-05-17       Impact factor: 2.188

9.  Evidence of association between hepatitis C virus genotype 2b and nosocomial transmissions in hemodialysis centers from southern Brazil.

Authors:  Naylê Maria Oliveira da Silva; Fabiana Nunes Germano; Raul Andres Mendoza-Sassi; Hector Nicolas Seuánez; Marcelo Alves Soares; Ana Maria Barral de Martinez
Journal:  Virol J       Date:  2013-05-29       Impact factor: 4.099

10.  Update of KDBI: Kinetic Data of Bio-molecular Interaction database.

Authors:  Pankaj Kumar; B C Han; Z Shi; J Jia; Y P Wang; Y T Zhang; L Liang; Q F Liu; Z L Ji; Y Z Chen
Journal:  Nucleic Acids Res       Date:  2008-10-29       Impact factor: 16.971

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.